Drug Trial Radar · NCT06952504
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,123
Planned (sponsor's estimate)
Start
May 22, 2025
Primary completion
May 24, 2032
Study completion May 24, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Conditions
- Endometrial Cancer
Interventions
PembrolizumabBiological
Intravenous (IV) Infusion
CarboplatinDrug
During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
PaclitaxelDrug
During the Induction Phase, participants receive paclitaxel 175 mg/m\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
DocetaxelDrug
During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.
Sacituzumab TirumotecanBiological
IV Infusion
CisplatinDrug
During the Induction Phase, participants may receive cisplatin (in place of carboplatin) 75 mg/m\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maintenance Treatment: Progression-Free Survival (PFS)Time frame: Up to approximately 44 months
- Maintenance Treatment: Overall Survival (OS)Time frame: Up to approximately 54 months
Locations
272 sites in 34 countries. Site status is shown where the registry gives one.
University of South Alabama, Mitchell Cancer Institute ( Site 6033)
Mobile, Alabama · Recruiting
Alaska Women's Cancer Care ( Site 6036)
Anchorage, Alaska · Recruiting
CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014)
Irvine, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020)
Orange, California · Recruiting
Sansum Clinic (Ridley Tree) ( Site 8007)
Solvang, California · Recruiting
John Muir Health Cancer Center ( Site 6028)
Walnut Creek, California · Recruiting
Yale University School of Medicine ( Site 6009)
New Haven, Connecticut · Recruiting
MedStar Washington Hospital Center ( Site 5005)
Washington D.C., District of Columbia · Recruiting
Florida Cancer Specialists - South ( Site 7003)
Fort Myers, Florida · Recruiting
UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026)
Gainesville, Florida · Recruiting
Mount Sinai Braman Comprehensive Cancer Center ( Site 6031)
Miami Beach, Florida · Recruiting
AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)
Orlando, Florida · Recruiting
Florida Cancer Specialists ( Site 7002)
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists East ( Site 7001)
West Palm Beach, Florida · Recruiting
St. Joseph's/Candler Health System ( Site 6021)
Savannah, Georgia · Recruiting
University of Chicago Medical Center ( Site 5002)
Chicago, Illinois · Recruiting
Parkview Research Center ( Site 6008)
Fort Wayne, Indiana · Recruiting
Women's Cancer Care ( Site 6010)
Covington, Louisiana · Recruiting
TRIALS 365 ( Site 6005)
Shreveport, Louisiana · Recruiting
Maine Medical Center - Scarborough Campus ( Site 6042)
Scarborough, Maine · Recruiting
Tufts Medical Center ( Site 6052)
Boston, Massachusetts · Recruiting
Minnesota Oncology Hematology, PA ( Site 8003)
Minneapolis, Minnesota · Recruiting
St. Dominic's Hospital ( Site 5004)
Jackson, Mississippi · Recruiting
Washington University - School of Medicine ( Site 5006)
St Louis, Missouri · Recruiting
The Center of Hope ( Site 5018)
Reno, Nevada · Recruiting
Holy Name Medical Center ( Site 6011)
Teaneck, New Jersey · Recruiting
University of New Mexico Comprehensive Cancer Center ( Site 6046)
Albuquerque, New Mexico · Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 6055)
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004)
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 6053)
New York, New York · Recruiting
Duke Cancer Institute ( Site 6049)
Durham, North Carolina · Recruiting
FirstHealth of the Carolinas ( Site 6037)
Pinehurst, North Carolina · Recruiting
Miami Valley Hospital South ( Site 6014)
Centerville, Ohio · Recruiting
University of Cincinnati Medical Center ( Site 5013)
Cincinnati, Ohio · Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
Columbus, Ohio · Recruiting
Kettering Health Main Campus-Kettering Health Cancer Center ( Site 5001)
Kettering, Ohio · Recruiting
University of Oklahoma Health Sciences Center, Stephenson Cancer Center ( Site 6012)
Oklahoma City, Oklahoma · Recruiting
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6047)
Tulsa, Oklahoma · Recruiting
Oncology Associates of Oregon, P.C. ( Site 8005)
Eugene, Oregon · Recruiting
St. Luke's University Health Network ( Site 6041)
Bethlehem, Pennsylvania · Recruiting
Showing 40 of 272 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.